Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours

Sjoukje F. Oosting; Astrid A.M. van der Veldt; Rudolf S.N. Fehrmann; Corine H. GeurtsvanKessel; Rob S. van Binnendijk; Anne Marie C. Dingemans; Egbert F. Smit; T. Jeroen N. Hiltermann; Gerco den Hartog; Mathilda Jalving; Tatjana T. Westphal; Arkajyoti Bhattacharya; Faye de Wilt; Annemarie Boerma; Lisanne van Zijl; Guus F. Rimmelzwaan; Pia Kvistborg; Cecile A.C.M. van Els; Nynke Y. Rots; Debbie van Baarle; John B.A.G. Haanen; Elisabeth G.E. de Vries

doi:10.1016/S1470-2045(22)00203-0

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours

Sjoukje F. Oosting, Astrid A.M. van der Veldt^*, Rudolf S.N. Fehrmann, Corine H. GeurtsvanKessel, Rob S. van Binnendijk, Anne Marie C. Dingemans, Egbert F. Smit, T. Jeroen N. Hiltermann, Gerco den Hartog, Mathilda Jalving, Tatjana T. Westphal, Arkajyoti Bhattacharya, Faye de Wilt, Annemarie Boerma, Lisanne van Zijl, Guus F. Rimmelzwaan, Pia Kvistborg, Cecile A.C.M. van Els, Nynke Y. Rots, Debbie van BaarleJohn B.A.G. Haanen, Elisabeth G.E. de Vries

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

19 Citations (Scopus)

39 Downloads (Pure)

Original language	English
Pages (from-to)	833-835
Number of pages	3
Journal	The Lancet Oncology
Volume	23
Issue number	7
Early online date	27 Jun 2022
DOIs	https://doi.org/10.1016/S1470-2045(22)00203-0
Publication status	Published - 1 Jul 2022

Bibliographical note

Funding Information:
SFO reports research grants from Novartis and Celldex Therapeutics, and consultancy fees from Bristol Myers Squibb (BMS; all paid to the institution). AAMvdV reports consultancy fees from BMS, Merck Sharp & Dohme (MSD), Merck, Sanofi, Eisai, Pfizer, Ipsen, Roche, Pierre Fabre, and Novartis, and travel support from Bayer, Roche, Novartis, and Pfizer (all paid to the institution). A-MCD reports consultancy fees from Roche, Boehringer Ingelheim, Amgen, Bayer, Pharmamar, and Sanofi (all paid to the institution); speaker fees from Eli Lilly, AstraZeneca, Jansen, Chiesi, and Takeda (all paid to the institution); and research support from BMS, AbbVie, and Amgen (all paid to the institution). EFS reports consultancy fees from Eli Lilly (all paid to the institution); speaker fees from AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo (all paid to the institution); and advisory board fees from AstraZeneca, Bayer, BMS, MSD, Merck, Novartis, Pfizer, Roche Genentech, Roche Diagnostics, and Takeda (all paid to the institution). TJNH reports advisory board fees from BMS, AstraZeneca, Merck, Pfizer, Roche, and MSD (all paid to the institution). MJ reports consultancy fees from AstraZeneca and Pierre Fabre (all paid to the institution). GFR reports funding from the Alexander von Humboldt Foundation (paid to the institution). JBAGH reports consultancy fees from Achilles Therapeutics, BioNTech, BMS, Immunocore, Instil Bio, Molecular Partners, MSD, Gadeta, Merck Serono, Neogene Therapeutics, Novartis, Pfizer, PokeAcel, Roche/Genentech, Sanofi, and T-Knife (paid to the institution); consultancy fees from Neogene Tx; speaker fees from Ipsen, Eisai, and Novartis (paid to the institution); research grants from Asher-Bio, BMS, BioNTech, MSD, and Novartis (paid to the institution); and stock in Neogene Tx. EGEdV reports an advisory role at Daiichi Sankyo, NSABP, and Sanofi, and research funding from Amgen, AstraZeneca, Bayer, Chugai Pharma, Crescendo, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier, and Synthon (all paid to the institution). All other authors declare no competing interests. The study is funded by ZonMw, the Netherlands Organisation for Health Research and Development. SFO and AAMvdV contributed equally.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(22)00203-0Licence: Unspecified

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumoursFinal published version, 419 KBLicence: Unspecified

Cite this

Oosting, S. F., van der Veldt, A. A. M., Fehrmann, R. S. N., GeurtsvanKessel, C. H., van Binnendijk, R. S., Dingemans, A. M. C., Smit, E. F., Hiltermann, T. J. N., den Hartog, G., Jalving, M., Westphal, T. T., Bhattacharya, A., de Wilt, F., Boerma, A., van Zijl, L., Rimmelzwaan, G. F., Kvistborg, P., van Els, C. A. C. M., Rots, N. Y., ... de Vries, E. G. E. (2022). Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. The Lancet Oncology, 23(7), 833-835. https://doi.org/10.1016/S1470-2045(22)00203-0

@article{02ea2a455d91436c8c819f64ad459b32,

title = "Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours",

author = "Oosting, {Sjoukje F.} and {van der Veldt}, {Astrid A.M.} and Fehrmann, {Rudolf S.N.} and GeurtsvanKessel, {Corine H.} and {van Binnendijk}, {Rob S.} and Dingemans, {Anne Marie C.} and Smit, {Egbert F.} and Hiltermann, {T. Jeroen N.} and {den Hartog}, Gerco and Mathilda Jalving and Westphal, {Tatjana T.} and Arkajyoti Bhattacharya and {de Wilt}, Faye and Annemarie Boerma and {van Zijl}, Lisanne and Rimmelzwaan, {Guus F.} and Pia Kvistborg and {van Els}, {Cecile A.C.M.} and Rots, {Nynke Y.} and {van Baarle}, Debbie and Haanen, {John B.A.G.} and {de Vries}, {Elisabeth G.E.}",

note = "Funding Information: SFO reports research grants from Novartis and Celldex Therapeutics, and consultancy fees from Bristol Myers Squibb (BMS; all paid to the institution). AAMvdV reports consultancy fees from BMS, Merck Sharp & Dohme (MSD), Merck, Sanofi, Eisai, Pfizer, Ipsen, Roche, Pierre Fabre, and Novartis, and travel support from Bayer, Roche, Novartis, and Pfizer (all paid to the institution). A-MCD reports consultancy fees from Roche, Boehringer Ingelheim, Amgen, Bayer, Pharmamar, and Sanofi (all paid to the institution); speaker fees from Eli Lilly, AstraZeneca, Jansen, Chiesi, and Takeda (all paid to the institution); and research support from BMS, AbbVie, and Amgen (all paid to the institution). EFS reports consultancy fees from Eli Lilly (all paid to the institution); speaker fees from AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo (all paid to the institution); and advisory board fees from AstraZeneca, Bayer, BMS, MSD, Merck, Novartis, Pfizer, Roche Genentech, Roche Diagnostics, and Takeda (all paid to the institution). TJNH reports advisory board fees from BMS, AstraZeneca, Merck, Pfizer, Roche, and MSD (all paid to the institution). MJ reports consultancy fees from AstraZeneca and Pierre Fabre (all paid to the institution). GFR reports funding from the Alexander von Humboldt Foundation (paid to the institution). JBAGH reports consultancy fees from Achilles Therapeutics, BioNTech, BMS, Immunocore, Instil Bio, Molecular Partners, MSD, Gadeta, Merck Serono, Neogene Therapeutics, Novartis, Pfizer, PokeAcel, Roche/Genentech, Sanofi, and T-Knife (paid to the institution); consultancy fees from Neogene Tx; speaker fees from Ipsen, Eisai, and Novartis (paid to the institution); research grants from Asher-Bio, BMS, BioNTech, MSD, and Novartis (paid to the institution); and stock in Neogene Tx. EGEdV reports an advisory role at Daiichi Sankyo, NSABP, and Sanofi, and research funding from Amgen, AstraZeneca, Bayer, Chugai Pharma, Crescendo, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier, and Synthon (all paid to the institution). All other authors declare no competing interests. The study is funded by ZonMw, the Netherlands Organisation for Health Research and Development. SFO and AAMvdV contributed equally. ",

year = "2022",

month = jul,

day = "1",

doi = "10.1016/S1470-2045(22)00203-0",

language = "English",

volume = "23",

pages = "833--835",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "7",

}

Oosting, SF, van der Veldt, AAM, Fehrmann, RSN, GeurtsvanKessel, CH, van Binnendijk, RS, Dingemans, AMC, Smit, EF, Hiltermann, TJN, den Hartog, G, Jalving, M, Westphal, TT, Bhattacharya, A, de Wilt, F, Boerma, A, van Zijl, L, Rimmelzwaan, GF, Kvistborg, P, van Els, CACM, Rots, NY, van Baarle, D, Haanen, JBAG & de Vries, EGE 2022, 'Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours', The Lancet Oncology, vol. 23, no. 7, pp. 833-835. https://doi.org/10.1016/S1470-2045(22)00203-0

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. / Oosting, Sjoukje F.; van der Veldt, Astrid A.M.; Fehrmann, Rudolf S.N. et al.
In: The Lancet Oncology, Vol. 23, No. 7, 01.07.2022, p. 833-835.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours

AU - Oosting, Sjoukje F.

AU - van der Veldt, Astrid A.M.

AU - Fehrmann, Rudolf S.N.

AU - GeurtsvanKessel, Corine H.

AU - van Binnendijk, Rob S.

AU - Dingemans, Anne Marie C.

AU - Smit, Egbert F.

AU - Hiltermann, T. Jeroen N.

AU - den Hartog, Gerco

AU - Jalving, Mathilda

AU - Westphal, Tatjana T.

AU - Bhattacharya, Arkajyoti

AU - de Wilt, Faye

AU - Boerma, Annemarie

AU - van Zijl, Lisanne

AU - Rimmelzwaan, Guus F.

AU - Kvistborg, Pia

AU - van Els, Cecile A.C.M.

AU - Rots, Nynke Y.

AU - van Baarle, Debbie

AU - Haanen, John B.A.G.

AU - de Vries, Elisabeth G.E.

N1 - Funding Information: SFO reports research grants from Novartis and Celldex Therapeutics, and consultancy fees from Bristol Myers Squibb (BMS; all paid to the institution). AAMvdV reports consultancy fees from BMS, Merck Sharp & Dohme (MSD), Merck, Sanofi, Eisai, Pfizer, Ipsen, Roche, Pierre Fabre, and Novartis, and travel support from Bayer, Roche, Novartis, and Pfizer (all paid to the institution). A-MCD reports consultancy fees from Roche, Boehringer Ingelheim, Amgen, Bayer, Pharmamar, and Sanofi (all paid to the institution); speaker fees from Eli Lilly, AstraZeneca, Jansen, Chiesi, and Takeda (all paid to the institution); and research support from BMS, AbbVie, and Amgen (all paid to the institution). EFS reports consultancy fees from Eli Lilly (all paid to the institution); speaker fees from AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo (all paid to the institution); and advisory board fees from AstraZeneca, Bayer, BMS, MSD, Merck, Novartis, Pfizer, Roche Genentech, Roche Diagnostics, and Takeda (all paid to the institution). TJNH reports advisory board fees from BMS, AstraZeneca, Merck, Pfizer, Roche, and MSD (all paid to the institution). MJ reports consultancy fees from AstraZeneca and Pierre Fabre (all paid to the institution). GFR reports funding from the Alexander von Humboldt Foundation (paid to the institution). JBAGH reports consultancy fees from Achilles Therapeutics, BioNTech, BMS, Immunocore, Instil Bio, Molecular Partners, MSD, Gadeta, Merck Serono, Neogene Therapeutics, Novartis, Pfizer, PokeAcel, Roche/Genentech, Sanofi, and T-Knife (paid to the institution); consultancy fees from Neogene Tx; speaker fees from Ipsen, Eisai, and Novartis (paid to the institution); research grants from Asher-Bio, BMS, BioNTech, MSD, and Novartis (paid to the institution); and stock in Neogene Tx. EGEdV reports an advisory role at Daiichi Sankyo, NSABP, and Sanofi, and research funding from Amgen, AstraZeneca, Bayer, Chugai Pharma, Crescendo, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier, and Synthon (all paid to the institution). All other authors declare no competing interests. The study is funded by ZonMw, the Netherlands Organisation for Health Research and Development. SFO and AAMvdV contributed equally.

PY - 2022/7/1

Y1 - 2022/7/1

UR - http://www.scopus.com/inward/record.url?scp=85133580903&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(22)00203-0

DO - 10.1016/S1470-2045(22)00203-0

M3 - Comment/Letter to the editor

C2 - 35483383

AN - SCOPUS:85133580903

SN - 1470-2045

VL - 23

SP - 833

EP - 835

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 7

ER -

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this